The Experts below are selected from a list of 25011 Experts worldwide ranked by ideXlab platform

Bertil Abrahamsson - One of the best experts on this subject based on the ideXlab platform.

  • toward an increased understanding of the barriers to colonic drug absorption in humans implications for early controlled Release Candidate assessment
    Molecular Pharmaceutics, 2009
    Co-Authors: Christer Tannergren, Anna Bergendal, Hans Lennernas, Bertil Abrahamsson
    Abstract:

    The purpose of this study was to increase the understanding of in vivo colonic drug absorption in humans by summarizing and evaluating all regional in vivo human absorption data with focus on the interpretation of the colonic absorption data in relation to intestinal permeability and solubility. In addition, the usefulness of the Biopharmaceutics Classification System (BCS) in early assessment of the in vivo colonic absorption potential of controlled Release drug Candidates was investigated. Clinical regional absorption data (Cmax, Tmax, and AUC) of 42 drugs were collected from journal articles, abstracts, and internal reports, and the relative bioavailability in the colon (Frelcolon) was obtained directly or calculated. Bioavailability, fraction dose absorbed, and information if the compounds were substrates for P-glycoprotein (P-gp) or cytochrome P450 3A (CYP3A) were also obtained. The BCS I drugs were well absorbed in the colon (Frelcolon > 70%), although some drugs had lower values due to bacterial de...

  • toward an increased understanding of the barriers to colonic drug absorption in humans implications for early controlled Release Candidate assessment
    Molecular Pharmaceutics, 2009
    Co-Authors: Christer Tannergren, Anna Bergendal, Hans Lennernas, Bertil Abrahamsson
    Abstract:

    The purpose of this study was to increase the understanding of in vivo colonic drug absorption in humans by summarizing and evaluating all regional in vivo human absorption data with focus on the interpretation of the colonic absorption data in relation to intestinal permeability and solubility. In addition, the usefulness of the Biopharmaceutics Classification System (BCS) in early assessment of the in vivo colonic absorption potential of controlled Release drug Candidates was investigated. Clinical regional absorption data (Cmax, Tmax, and AUC) of 42 drugs were collected from journal articles, abstracts, and internal reports, and the relative bioavailability in the colon (Frel(colon)) was obtained directly or calculated. Bioavailability, fraction dose absorbed, and information if the compounds were substrates for P-glycoprotein (P-gp) or cytochrome P450 3A (CYP3A) were also obtained. The BCS I drugs were well absorbed in the colon (Frel(colon) > 70%), although some drugs had lower values due to bacterial degradation in the colon. The low permeability drugs (BCS III/IV) had a lower degree of absorption in the colon (Frel(colon) < 50%). There was a clear correlation between in vitro Caco-2 permeability and Frel(colon), and atenolol and metoprolol may function as permeability markers for low and high colonic absorption, respectively. No obvious effect of P-gp on the colonic absorption of the drugs in this study was detected. There was insufficient data available to fully assess the impact of low solubility and slow dissolution rate. The estimated in vivo fractions dissolved of the only two compounds administered to the colon as both a solution and as solid particles were 55% and 92%, respectively. In conclusion, permeability and solubility are important barriers to colonic absorption in humans, and in vitro testing of these properties is recommended in early assessment of colonic absorption potential.

Christer Tannergren - One of the best experts on this subject based on the ideXlab platform.

  • toward an increased understanding of the barriers to colonic drug absorption in humans implications for early controlled Release Candidate assessment
    Molecular Pharmaceutics, 2009
    Co-Authors: Christer Tannergren, Anna Bergendal, Hans Lennernas, Bertil Abrahamsson
    Abstract:

    The purpose of this study was to increase the understanding of in vivo colonic drug absorption in humans by summarizing and evaluating all regional in vivo human absorption data with focus on the interpretation of the colonic absorption data in relation to intestinal permeability and solubility. In addition, the usefulness of the Biopharmaceutics Classification System (BCS) in early assessment of the in vivo colonic absorption potential of controlled Release drug Candidates was investigated. Clinical regional absorption data (Cmax, Tmax, and AUC) of 42 drugs were collected from journal articles, abstracts, and internal reports, and the relative bioavailability in the colon (Frelcolon) was obtained directly or calculated. Bioavailability, fraction dose absorbed, and information if the compounds were substrates for P-glycoprotein (P-gp) or cytochrome P450 3A (CYP3A) were also obtained. The BCS I drugs were well absorbed in the colon (Frelcolon > 70%), although some drugs had lower values due to bacterial de...

  • toward an increased understanding of the barriers to colonic drug absorption in humans implications for early controlled Release Candidate assessment
    Molecular Pharmaceutics, 2009
    Co-Authors: Christer Tannergren, Anna Bergendal, Hans Lennernas, Bertil Abrahamsson
    Abstract:

    The purpose of this study was to increase the understanding of in vivo colonic drug absorption in humans by summarizing and evaluating all regional in vivo human absorption data with focus on the interpretation of the colonic absorption data in relation to intestinal permeability and solubility. In addition, the usefulness of the Biopharmaceutics Classification System (BCS) in early assessment of the in vivo colonic absorption potential of controlled Release drug Candidates was investigated. Clinical regional absorption data (Cmax, Tmax, and AUC) of 42 drugs were collected from journal articles, abstracts, and internal reports, and the relative bioavailability in the colon (Frel(colon)) was obtained directly or calculated. Bioavailability, fraction dose absorbed, and information if the compounds were substrates for P-glycoprotein (P-gp) or cytochrome P450 3A (CYP3A) were also obtained. The BCS I drugs were well absorbed in the colon (Frel(colon) > 70%), although some drugs had lower values due to bacterial degradation in the colon. The low permeability drugs (BCS III/IV) had a lower degree of absorption in the colon (Frel(colon) < 50%). There was a clear correlation between in vitro Caco-2 permeability and Frel(colon), and atenolol and metoprolol may function as permeability markers for low and high colonic absorption, respectively. No obvious effect of P-gp on the colonic absorption of the drugs in this study was detected. There was insufficient data available to fully assess the impact of low solubility and slow dissolution rate. The estimated in vivo fractions dissolved of the only two compounds administered to the colon as both a solution and as solid particles were 55% and 92%, respectively. In conclusion, permeability and solubility are important barriers to colonic absorption in humans, and in vitro testing of these properties is recommended in early assessment of colonic absorption potential.

Hans Lennernas - One of the best experts on this subject based on the ideXlab platform.

  • toward an increased understanding of the barriers to colonic drug absorption in humans implications for early controlled Release Candidate assessment
    Molecular Pharmaceutics, 2009
    Co-Authors: Christer Tannergren, Anna Bergendal, Hans Lennernas, Bertil Abrahamsson
    Abstract:

    The purpose of this study was to increase the understanding of in vivo colonic drug absorption in humans by summarizing and evaluating all regional in vivo human absorption data with focus on the interpretation of the colonic absorption data in relation to intestinal permeability and solubility. In addition, the usefulness of the Biopharmaceutics Classification System (BCS) in early assessment of the in vivo colonic absorption potential of controlled Release drug Candidates was investigated. Clinical regional absorption data (Cmax, Tmax, and AUC) of 42 drugs were collected from journal articles, abstracts, and internal reports, and the relative bioavailability in the colon (Frelcolon) was obtained directly or calculated. Bioavailability, fraction dose absorbed, and information if the compounds were substrates for P-glycoprotein (P-gp) or cytochrome P450 3A (CYP3A) were also obtained. The BCS I drugs were well absorbed in the colon (Frelcolon > 70%), although some drugs had lower values due to bacterial de...

  • toward an increased understanding of the barriers to colonic drug absorption in humans implications for early controlled Release Candidate assessment
    Molecular Pharmaceutics, 2009
    Co-Authors: Christer Tannergren, Anna Bergendal, Hans Lennernas, Bertil Abrahamsson
    Abstract:

    The purpose of this study was to increase the understanding of in vivo colonic drug absorption in humans by summarizing and evaluating all regional in vivo human absorption data with focus on the interpretation of the colonic absorption data in relation to intestinal permeability and solubility. In addition, the usefulness of the Biopharmaceutics Classification System (BCS) in early assessment of the in vivo colonic absorption potential of controlled Release drug Candidates was investigated. Clinical regional absorption data (Cmax, Tmax, and AUC) of 42 drugs were collected from journal articles, abstracts, and internal reports, and the relative bioavailability in the colon (Frel(colon)) was obtained directly or calculated. Bioavailability, fraction dose absorbed, and information if the compounds were substrates for P-glycoprotein (P-gp) or cytochrome P450 3A (CYP3A) were also obtained. The BCS I drugs were well absorbed in the colon (Frel(colon) > 70%), although some drugs had lower values due to bacterial degradation in the colon. The low permeability drugs (BCS III/IV) had a lower degree of absorption in the colon (Frel(colon) < 50%). There was a clear correlation between in vitro Caco-2 permeability and Frel(colon), and atenolol and metoprolol may function as permeability markers for low and high colonic absorption, respectively. No obvious effect of P-gp on the colonic absorption of the drugs in this study was detected. There was insufficient data available to fully assess the impact of low solubility and slow dissolution rate. The estimated in vivo fractions dissolved of the only two compounds administered to the colon as both a solution and as solid particles were 55% and 92%, respectively. In conclusion, permeability and solubility are important barriers to colonic absorption in humans, and in vitro testing of these properties is recommended in early assessment of colonic absorption potential.

Anna Bergendal - One of the best experts on this subject based on the ideXlab platform.

  • toward an increased understanding of the barriers to colonic drug absorption in humans implications for early controlled Release Candidate assessment
    Molecular Pharmaceutics, 2009
    Co-Authors: Christer Tannergren, Anna Bergendal, Hans Lennernas, Bertil Abrahamsson
    Abstract:

    The purpose of this study was to increase the understanding of in vivo colonic drug absorption in humans by summarizing and evaluating all regional in vivo human absorption data with focus on the interpretation of the colonic absorption data in relation to intestinal permeability and solubility. In addition, the usefulness of the Biopharmaceutics Classification System (BCS) in early assessment of the in vivo colonic absorption potential of controlled Release drug Candidates was investigated. Clinical regional absorption data (Cmax, Tmax, and AUC) of 42 drugs were collected from journal articles, abstracts, and internal reports, and the relative bioavailability in the colon (Frelcolon) was obtained directly or calculated. Bioavailability, fraction dose absorbed, and information if the compounds were substrates for P-glycoprotein (P-gp) or cytochrome P450 3A (CYP3A) were also obtained. The BCS I drugs were well absorbed in the colon (Frelcolon > 70%), although some drugs had lower values due to bacterial de...

  • toward an increased understanding of the barriers to colonic drug absorption in humans implications for early controlled Release Candidate assessment
    Molecular Pharmaceutics, 2009
    Co-Authors: Christer Tannergren, Anna Bergendal, Hans Lennernas, Bertil Abrahamsson
    Abstract:

    The purpose of this study was to increase the understanding of in vivo colonic drug absorption in humans by summarizing and evaluating all regional in vivo human absorption data with focus on the interpretation of the colonic absorption data in relation to intestinal permeability and solubility. In addition, the usefulness of the Biopharmaceutics Classification System (BCS) in early assessment of the in vivo colonic absorption potential of controlled Release drug Candidates was investigated. Clinical regional absorption data (Cmax, Tmax, and AUC) of 42 drugs were collected from journal articles, abstracts, and internal reports, and the relative bioavailability in the colon (Frel(colon)) was obtained directly or calculated. Bioavailability, fraction dose absorbed, and information if the compounds were substrates for P-glycoprotein (P-gp) or cytochrome P450 3A (CYP3A) were also obtained. The BCS I drugs were well absorbed in the colon (Frel(colon) > 70%), although some drugs had lower values due to bacterial degradation in the colon. The low permeability drugs (BCS III/IV) had a lower degree of absorption in the colon (Frel(colon) < 50%). There was a clear correlation between in vitro Caco-2 permeability and Frel(colon), and atenolol and metoprolol may function as permeability markers for low and high colonic absorption, respectively. No obvious effect of P-gp on the colonic absorption of the drugs in this study was detected. There was insufficient data available to fully assess the impact of low solubility and slow dissolution rate. The estimated in vivo fractions dissolved of the only two compounds administered to the colon as both a solution and as solid particles were 55% and 92%, respectively. In conclusion, permeability and solubility are important barriers to colonic absorption in humans, and in vitro testing of these properties is recommended in early assessment of colonic absorption potential.

Justin Reese - One of the best experts on this subject based on the ideXlab platform.

  • GMOD/Apollo: Release Candidate 1 - Apollo2.0.6(JB#9334e76fd)
    2017
    Co-Authors: Nathan Dunn, Colin Diesh, Robert Buels, Monica Munoz-torres, Eric Rasche, Stephen Ficklin, Justin Reese
    Abstract:

    Apollo 2.0.6 Release Candidate 1 (testing only) Some of the new features include: Numerous UI and performance improvements including an additional icon to show the native track panel. Some important bug fixes: Transcripts of pseudogenes should NOT have the word 'transcript' or other type in the name. Problems loading list of Tracks when switching organisms on slower connection. The complete change log can be found at: https://github.com/GMOD/Apollo/blob/master/ChangeLog.md Please review the documentation pages for more details: http://genomearchitect.readthedocs.io/en/stable/ Note: You can find a guide upgrading existing Apollo installations here: http://genomearchitect.readthedocs.io/en/stable/Migration.html Please open a GitHub issue if you find any problems: https://github.com/GMOD/Apollo/issues/ Active mailing list (apollo@lists.lbl.gov) and archive

  • GMOD/Apollo: Release Candidate 4 - Apollo2.0.5-RC4(JB-#9334e76fd)
    2016
    Co-Authors: Nathan Dunn, Colin Diesh, Robert Buels, Monica Munoz-torres, Eric Rasche, Stephen Ficklin, Justin Reese
    Abstract:

    Release Candidate 4 - Apollo 2.0.5 (still testing) Some of the new features include: Numerous UI and performance improvements, including easier navigation between annotated elements via the Annotator Panel. Better server and client-side reporting. Upgrade to Java 8 / GWT 2.8, and updated JBrowse (use ./apollo clean-all or install from an formal Release download) It is now possible to also include metadata on import. Some important bug fixes: Import script were logging preferences unnecessarily. Improved security for non-public genomes. Fixed for going between logged-out mode and the Annotator Panel while retaining history. Improved display of sequence over the annotation after moving the annotation to the opposite strand. Users will see a warning when it is not possible to create an intron with canonical splice sites in the selected region. The complete change log can be found at: https://github.com/GMOD/Apollo/blob/master/ChangeLog.md Please review the documentation pages for more details: http://genomearchitect.readthedocs.io/en/latest/ Note: You can find a guide upgrading existing Apollo installations here: http://genomearchitect.readthedocs.io/en/stable/Migration.html Please open a GitHub issue if you find any problems: https://github.com/GMOD/Apollo/issues/ Active mailing list apollo@lists.lbl.go